Arzneimittelforschung 2012; 62(01): 9-13
DOI: 10.1055/s-0031-1291361
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Bioequivalence Evaluation of Cefdinir in Healthy Fasting Subjects

Authors

  • J. Chen

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • B. Jiang

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • H. Lou

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • L. Yu

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • Z. Ruan

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
Further Information

Publication History

received 15 September 2011

accepted 17 October 2011

Publication Date:
10 January 2012 (online)

Preview

Abstract

A simple and sensitive HPLC method was developed to determine cefdinir (CAS 91832-40-5) in human plasma. The method was validated by investigating the accuracy and precision for intra- and inter-day runs in a linear concentration from 0.05–2.0 µg/ml. The object of this study was to compare the bioavailability of cefdinir capsule (reference) and cefdinir granule (test) containing 100 mg of cefdinir. A randomized, open-label, single-dose, 2-way crossover bioequivalence study in 20 healthy, Chinese, male subjects was conducted. A 1-week wash-out period was applied. Blood samples were collected before and with 10 h after drug administration. The formulations were compared using the following pharmacokinetic parameters: AUC0-t, AUC0-∞ and C max. The 90% confidence interval (CI) of the ratios of log-transformed AUC0-t and AUC0-∞ were used to assess bioequivalence between the 2 formulations using the equivalence interval of 80 and 125%. The results showed that the 90% CI of the ratios of AUC0-t, AUC0-∞ and C max were 102.5% (94.7–111.0%), 103.4% (94.8–112.7%) and 106.4% (97.0–116.7%), respectively, which indicated 2 formulations of cefidinir are bioequivalent. Both treatments showed similar tolerability and safety.